Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.65 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.63 |
| ▸ | LTA4H | P09960 | 4/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29500180 | 1.00 | LMNA (0.72) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| Hydrochloric Acid SCHEMBL9386460 | 0.98 | LMNA (0.69) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL27968872 | 0.98 | LMNA (0.69) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| Bromide SCHEMBL9391382 | 0.98 | LMNA (0.69) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL16114401 | 0.93 | LMNA (0.75) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL30535283 | 0.93 | LMNA (0.82) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL676142 | 0.93 | LMNA (0.82) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| Potassium SCHEMBL6776357 | 0.90 | LMNA (0.78) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| SCHEMBL6510014 | 0.88 | TDP1 (0.58) | LMNATDP1CYP11B1CYP11B2CYP19A1 | |
| Sulfuric Acid SCHEMBL11641651 | 0.88 | TDP1 (0.58) | LMNATDP1CYP11B1CYP11B2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 691 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070231390-A1 | Formulations including hygroscopic compounds | ANDRX LABS, LLC (US) | 2007-10-04 | — | — | US | claimed |
| WO-1994002143-A1 | USE OF 3-PHENOXYPYRIDINE IN THE TREATMENT OF PSYCHOMOTOR STIMULANT ADDICTION | WARNER-LAMBERT COMPANY (US) | 1994-02-03 | — | — | WO | claimed |
| US-5232934-A | Administering 3-phenoxypyridine(or its acid addition salts) as nontoxic substitute for addictive stimulants | WARNER-LAMBERT CO. (US) | 1993-08-03 | — | — | US | claimed |
| EP-0345787-B1 | DRUG IN COMBINATION WITH FLAVOR MASKING AGENT AND METHOD FOR MAKING SAME | WARNER-LAMBERT COMPANY (US) | 1992-11-11 | — | — | EP | claimed |
| US-4910023-A | Containing silica | WARNER-LAMBERT COMPANY (US) | 1990-03-20 | — | — | US | claimed |
| EP-0345787-A2 | Drug in combination with flavor masking agent and method for making same | WARNER-LAMBERT COMPANY (US) | 1989-12-13 | — | — | EP | claimed |
| EP-0116781-B1 | PHARMACEUTICAL COMPOSITIONS IN ORAL DOSAGE FORM | WARNER-LAMBERT COMPANY (US) | 1989-08-02 | — | — | EP | claimed |
| EP-0239527-A2 | Composition adopted for use as a transdermal formulation | WARNER-LAMBERT COMPANY (US) | 1987-09-30 | — | — | EP | claimed |
| EP-0116781-A1 | Pharmaceutical compositions in oral dosage form | WARNER-LAMBERT COMPANY (US) | 1984-08-29 | — | — | EP | claimed |
| US-4434169-A | MEMORY LOSS, 3-PHENOXYPYRIDINE | WARNER-LAMBERT COMPANY (US) | 1984-02-28 | — | — | US | claimed |
| US-4128555-A | 3-Phenoxypyridine monosulfate and a method for its production | WARNER-LAMBERT COMPANY (US) | 1978-12-05 | — | — | US | claimed |
| US-4067983-A | PSYCHOSTIMULATION USING 3-PHENOXYPYRIDINE | PARKE, DAVIS & COMPANY (US) | 1978-01-10 | — | — | US | claimed |
| US-4061756-A | Methods for treating cardiovascular disorders | PARKE, DAVIS & COMPANY (US) | 1977-12-06 | — | — | US | claimed |
| JP-2036130-A | — | — | None | — | — | JP | disclosed |
| JP-2028155-A | — | — | None | — | — | JP | disclosed |
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | PURDUE PHARMA L.P. (US) | 2026-01-08 | — | — | US | disclosed |
| US-4067983-A | PSYCHOSTIMULATION USING 3-PHENOXYPYRIDINE | PARKE, DAVIS & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-4067983-A | PSYCHOSTIMULATION USING 3-PHENOXYPYRIDINE | PARKE, DAVIS & COMPANY (US) | 1978-01-10 | — | — | US | disclosed |
| US-4061756-A | Methods for treating cardiovascular disorders | PARKE, DAVIS & COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
| US-4061756-A | Methods for treating cardiovascular disorders | PARKE, DAVIS & COMPANY (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007660-A1 | TREATMENT AND PREVENTION OF SLEEP DISORDERS | CRY1, PER2, SLC6A1 | LMNA 2057/4885TDP1 852/4885CYP11B1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.